Clinical Care Options Hepatitis - HBV http://clinicaloptions.com/hepatitis.aspx New treatment data and educational activities for hepatitis treating clinicians en-us Clinical Care Options Hepatitis - HBV http://images.imedoptions.com/img.asp?img=cco/CCO_Hep_RSS.gif http://clinicaloptions.com/hep Active Management of Oral Nucleos(t)ide Analogue Therapy for Hepatitis Bhttp://clinicaloptions.com/Hepatitis/Treatment%20Updates/HBV%20On%20Treatment/Virtual%20Presentation/Presentation.aspxJoin Ira M. Jacobson, MD, as he reviews on-treatment HBV guidelines including the relationships between early responses to oral anti-HBV agents and future treatment outcomes. On-Treatment Management of a Patient With Chronic Hepatitis B Receiving Adefovir Therapyhttp://clinicaloptions.com/Hepatitis/Treatment%20Updates/HBV%20On%20Treatment/Interactive%20Case%20Challenge/Case.aspxAlong with Kris V. Kowdley, MD, FACP, FACG, FASGE, AGAF, choose management strategies for a patient with chronic hepatitis B receiving treatment with adefovir. Special Hepatic Issues and Populationshttp://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Special%20Issues/Special%20Issues.aspxExpert Analysis from Robert J. Fontana, MD, Stephen A. Harrison, MD, LTC, MC, and David L. Thomas, MD, MPH. A Case-Based Approach to Managing Resistance in Chronic HBV Infection http://clinicaloptions.com/Hepatitis/Treatment%20Updates/Resistance%20in%20HBV/Virtual%20Presentations/Keeffe.aspx Emmet B. Keeffe, MD, MACP, reviews steps to prevent, identify and manage HBV resistance to oral agents. Clinical Updates in HBV Treatment http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/HBV%20Treatment.aspx Emmet B. Keeffe, MD, MACP, Fred Poordad, MD, and Paul Martin, MD discuss data from the meeting in Boston. Expert Recap: Clinical Updates in HBV Treatment http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Virtual%20Presentation%20Programs/HBV%20Treatment.aspx Watch and listen as Raymond T. Chung, MD, reviews key data and updates on hepatitis B management presented at the 2007 Boston liver disease meeting. Management of an HBeAg-Negative Patient With Lamivudine Resistance http://clinicaloptions.com/Hepatitis/Treatment%20Updates/HBV%20Case%20Debates/Interactive%20Case%20Challenges/Lamivudine%20Resistance.aspx Emmet B. Keeffe, MD, MACP, describes treatment strategies for managing emergence of lamivudine resistance in a patient with HBeAg-negative chronic hepatitis B. Pioglitazone Improves Liver Histology in Nondiabetic Patients With NASH http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/Special%20Issues/Capsules/132.aspx Pioglitazone treatment of NASH in nondiabetic patients appears to improve metabolic and histologic parameters, particularly liver injury and fibrosis. Management of an HBeAg-Positive Patient on Active Antiviral Therapy Who Has Failed to Achieve a Primary Response http://clinicaloptions.com/Hepatitis/Treatment%20Updates/HBV%20Case%20Debates/Interactive%20Case%20Challenges/Suboptimal%20Response.aspx Nezam H. Afdhal, MD, FRCPI, reviews management strategies for an HBeAg-positive Asian patient with chronic HBV infection. Management of a Treatment-Naive, HBeAg-Positive, Asian American Patient http://clinicaloptions.com/Hepatitis/Treatment%20Updates/HBV%20Case%20Debates/Interactive%20Case%20Challenges/Treatment-naive.aspx Jules L. Dienstag, MD, reviews the factors involved in selecting the optimal treatment in patients seeking first-line therapy for hepatitis B. Correlation Between HBV DNA and Liver Disease Progression Demonstrated in Chronic HBV Patients From Northeastern Greece During 12-Year Observational Study http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/898.aspx 12-year observational study reveals that elevated HBV DNA levels are associated with liver disease progression. No Survival Benefit Found With Nucleoside Analogue Use in HBV-Related Acute Liver Failure Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/95.aspx 10-year retrospective analysis suggests nucleoside analogue treatment not recommended for patients with HBV-related acute liver failure. Defining HBV Resistance: Interpreting and Applying Clinical Data http://clinicaloptions.com/Hepatitis/Treatment%20Updates/Resistance%20in%20HBV/Modules/Martin.aspx Paul Martin, MD, reviews the treatment of patients with chronic hepatitis B, focusing on drug resistance. Tenofovir Significantly Decreases HBV DNA in Lamivudine- and Adefovir-Experienced Patients With No Adefovir Resistance http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/83.aspx 12 months of tenofovir suppressed HBV DNA in 90% of HBV monoinfected patients with previous lamivudine and adefovir experience but no adefovir resistance. Entecavir Treatment in HBV Patients Achieves HBV DNA Reduction but Not HBV DNA Undetectability With Limited Response to Adefovir http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/951.aspx Entecavir reduces HBV DNA and ALT levels in patients with limited response to adefovir. Approximately One Half of HBeAg-Positive Initial Nonresponders to Entecavir Achieve Undetectable HBV DNA With Extended Treatment http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/997.aspx Most HBeAg-positive nonresponders to entecavir achieved ALT normalization in ETV-901 rollover study of extended entecavir treatment. GLOBE Study: Baseline and On-Treatment Predictors of Optimal Virologic Response to Telbivudine Identified for HBV Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/994.aspx Among nucleos(t)ide-naive hepatitis B patients participating in GLOBE trial, predictors have been identified for favorable efficacy outcomes and low resistance rates after 2 years of treatment with telbivudine Significantly Increased Risk of HCC in Chronic Hepatitis B HBsAg-Positive Patients With HBV DNA less than 104 copies/mL vs HBsAg-Seronegative Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/907.aspx HBsAg-positive patients with detectable HBV DNA less than 104 copies/mL have significantly increased risk of developing HCC than those with undetectable HBV DNA Tenofovir Demonstrates Significant Anti-HBV Activity in Adefovir-Resistant Chronic Hepatitis B Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/960.aspx Complete virologic suppression achieved in adefovir-resistant chronic hepatitis B patients following tenofovir therapy. Trajectory Modeling of REVEAL HBV DNA Subgroups Demonstrates That Increased Levels Over Time Associated With Increased HCC Risk http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/906.aspx Trajectory modeling of REVEAL data illustrates that changes in HBV DNA levels over time can predict the risk of developing HCC High HBsAg Seroconversion Rate Observed Among HBeAg-Positive Patients Who Achieved SVR to Standard Interferon Associated With Excellent Histologic Outcomes http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/991.aspx Long-term study reveals that interferon-based HBV therapy associated with significant HBsAg seroconversion rate and histologic improvements HBV DNA Level and Subgenotype as HCC Predictors in Chronic Hepatitis B Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/903.aspx High HBV DNA level and subgenotype Ce associated with higher risk of HCC Tenofovir Therapy Associated With Significantly Greater Efficacy and Comparable Safety vs Adefovir in HBeAg-Negative HBV Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/LB2.aspx Tenofovir therapy demonstrates robust efficacy and is well tolerated among HBeAg-negative chronic hepatitis B cohort Tenofovir Therapy Associated With Significantly Greater Efficacy and Comparable Safety vs Adefovir in HBeAg-Positive HBV Patients http://clinicaloptions.com/Hepatitis/Conference%20Coverage/Boston%202007/Tracks/HBV%20Treatment/Capsules/LB6.aspx Tenofovir therapy demonstrates robust efficacy and is well tolerated among HBeAg-positive chronic hepatitis B cohort